Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
2024年7月16日 - 10:00PM
Alkeus Pharmaceuticals, Inc. today announced that Tamara Dillon has
joined the company as Chief Human Resources Officer.
“Tamara is a strong leader with extensive commercial experience
and a proven track record of building small and large companies,
driving organizational growth, talent management and cultural
transformation,” said Michel Dahan, President and CEO of Alkeus
Pharmaceuticals. “Her exceptional expertise will be indispensable
as we prepare to scale the organization to support the development
and commercialization of gildeuretinol, our breakthrough-therapy
designated program with the potential to be the first therapy for
Stargardt disease. We are thrilled to have her on the executive
leadership team.”
Prior to joining Alkeus, Dillon served as the Chief People
Officer at Butterfly Network, Inc., where she led all aspects of
the company’s human resources function and corporate
communications, including culture, talent acquisition, learning and
development. Dillon's prior experience also includes almost eight
years as Chief People Officer at Akebia Therapeutics, where she
played an integral role in scaling the company, spearheaded a
multi-year culture transformation and managed enterprise-wide
change initiatives including merger integration. Her
responsibilities also included serving as Chief of Staff to the
CEO, as well as leading corporate reputation initiatives and the
patient advocacy function. Dillon previously held global leadership
roles at Novartis Institutes for BioMedical Research and Genzyme, a
Sanofi Company.
“Building a collaborative, inclusive and dynamic culture is
paramount to Alkeus’ success as we expand the organization,” Dillon
said. “I’m honored to have the opportunity to join the Alkeus team
at this pivotal moment in the company’s growth. Creating and
nurturing a strong purpose-driven culture will enable Alkeus to
thrive as we work together to achieve our mission to make a
meaningful difference in the lives of patients.”
About Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. is a private biopharmaceutical
company with headquarters in Cambridge, Mass., backed by
institutional investors led by Bain Capital Life Sciences. Founded
in 2010, Alkeus is developing therapies for serious diseases of the
eye with high unmet need. Alkeus’ breakthrough-designated lead
candidate, gildeuretinol acetate (ALK-001), is currently being
evaluated in clinical trials for the treatment of Stargardt disease
and for geographic atrophy (GA) secondary to age-related macular
degeneration (AMD).
About Gildeuretinol Acetate (ALK-001)
Gildeuretinol acetate (ALK-001) is a novel molecule created as a
specialized form of deuterated vitamin A designed to reduce the
dimerization of vitamin A without disrupting vision. In preclinical
studies, gildeuretinol decreased vitamin A dimerization to the
normal rate seen in unaffected individuals and prevented retinal
degeneration and loss of visual function in animals with Stargardt
disease. Gildeuretinol has received breakthrough therapy
designation and orphan drug designation from the U.S. Food and Drug
Administration. In addition to the TEASE trials, a Phase 3 (SAGA)
study of gildeuretinol in 200 patients with geographic atrophy (GA)
secondary to age-related macular degeneration (AMD) is expected to
read out topline data in 2024.
For further information, please contact:
Media@alkeuspharma.comWebsite: www.alkeuspharma.com